In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.
LBM415 activity against extracellular and intracellular Legionella pneumophila was studied. The LBM415 MIC50 for 20 Legionella sp. strains was 4 microg/ml, versus 0.06, 0.25, and <or=0.03 microg/ml for azithromycin, erythromycin, and levofloxacin, respectively. LBM415 (0.5 and 16 microg/ml) reversibly prevented intracellular growth of two L. pneumophila strains and was less active than erythromycin.
Edelstein
Paul H
PH
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine and Clinical Microbiology Laboratory, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA. phe@mail.med.upenn.edu
Hu
Baofeng
B
Edelstein
Martha A C
MA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D006168:Guinea Pigs; D006801:Humans; D007875:Legionella / Q000145:classification / Q000187:drug effects; D016952:Legionella pneumophila / Q000187:drug effects* / Q000254:growth & development*; D007876:Legionellosis / Q000382:microbiology; D007877:Legionnaires' Disease / Q000382:microbiology; D016676:Macrophages, Alveolar / Q000382:microbiology*; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; C487638:NVP PDF 713; D010455:Peptides